IBEX 35
11.022,90 -130,10 (-1,17%) Euro Stoxx 50
5.038,17 +22,07 (+0,44%) Dólar/Euro
1,0738 -0,0014 (-0,13%) Petróleo Brent
84,29 +0,71 (+0,85%) Oro
2.318,50 -3,80 (-0,16%) Bitcoin EUR
56.893,56 -1.250,59 (-2,15%)
Compugen Ltd. (CGEN)
Antes de la apertura:
Compugen Ltd.
Azrieli Center
Building D 26 Harokmim Street
Holon 5885849
Israel
972 3 765 8585
https://cgen.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 68
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Anat Cohen-Dayag Ph.D. | CEO, President & Director | 796,52k | N/A | 1967 |
| Dr. Zurit Levine Ph.D. | Senior Vice President of Technology Innovation | 345,7k | N/A | 1968 |
| Dr. Pierre Ferre Ph.D. | Vice President of Preclinical Development | 415,1k | N/A | 1977 |
| Mr. Alberto Sessa | Chief Financial Officer | N/A | N/A | 1962 |
| Dr. Eran Ophir Ph.D. | Chief Scientific Officer | N/A | N/A | 1978 |
| Ms. Yvonne Naughton | Head of Investor Relations & Corporate Communications | N/A | N/A | N/A |
| Mr. Eran Ben Dor | General Counsel & Corporate Secretary | N/A | N/A | N/A |
| Ms. Dorit Amitay | Vice President of Human Resources | N/A | N/A | 1968 |
| Dr. Yaron Turpaz M.B.A., Ph.D. | Senior VP & Senior Advisor of Data and Informatics Solutions | N/A | N/A | 1971 |
| Rivka Schwartz | Vice President Research and Discovery | N/A | N/A | N/A |
Descripción
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Gobierno corporativo
El ISS Governance QualityScore de Compugen Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
